Zobrazeno 1 - 10
of 288
pro vyhledávání: '"Patrizia Giannatempo"'
Autor:
Mimma Rizzo, Andrey Soares, Enrique Grande, Aristotelis Bamias, Ray Manneh Kopp, Edoardo Lenci, Thomas Buttner, Samer Salah, Francesco Grillone, Icaro Thiago de Carvalho, Jose Carlos Tapia, Calogero Gucciardino, Alvaro Pinto, Alessia Mennitto, Halima Abahssain, Pasquale Rescigno, Zin Myint, Hideki Takeshita, Gian Paolo Spinelli, Lazar Popovic, Maria Giuseppa Vitale, Ondrej Fiala, Patrizia Giannatempo, Roubini Zakopoulou, Francesco Carrozza, Francesco Massari, Fernando Sabino Marques Monteiro, Maria Paola Pace, Massimo Giannini, Giandomenico Roviello, Camillo Porta, Nicola Battelli, Ravindran Kanesvaran, Matteo Santoni
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of con
Externí odkaz:
https://doaj.org/article/7c7f88d7c9824bbc938bd6730c370b0e
Autor:
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in r
Externí odkaz:
https://doaj.org/article/104cb507efb6499da6d34e4000166944
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/4bdd5e1ba8d240d283f2ff88ab7806c4
Autor:
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica, Anna Patrikidou
Publikováno v:
Cancers, Vol 16, Iss 8, p 1465 (2024)
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a
Externí odkaz:
https://doaj.org/article/ff1490c61fa54f219f364636076fa1d2
Autor:
Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challeng
Externí odkaz:
https://doaj.org/article/5987142a35614d8f8862429246a6e6f1
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100369- (2021)
ABSTRACT: Introduction: One of the Non-Muscle Invasive Bladder Cancer (NMIBC) treatment options recently recommended by International Guidelines is represented by Active Surveillance (AS),. Herein we carried out a systematic review and pooled-analysi
Externí odkaz:
https://doaj.org/article/9e18327f729b4726a3ff778e92859c98
Autor:
Elisa Zanardi, Elena Verzoni, Paolo Grassi, Andrea Necchi, Patrizia Giannatempo, Daniele Raggi, Filippo De Braud, Giuseppe Procopio
Publikováno v:
Therapeutic Advances in Urology, Vol 7 (2015)
Temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) kinase, a protein that has been shown to be particularly active in metastatic renal cell carcinoma (mRCC) with poor prognosis. Therefore, temsirolimus should be considered as th
Externí odkaz:
https://doaj.org/article/14eef5fc218b4a62803295a88225d02f
Autor:
Giuseppe Fotia, Marco Stellato, Valentina Guadalupi, Pierangela Sepe, Melanie Claps, Patrizia Giannatempo, Achille Bottiglieri, Alessandro Rametta, Ida Taglialatela, Chiara Vela, Giuseppe Procopio, Elena Verzoni
Publikováno v:
Current Oncology Reports. 25:671-677
Autor:
Luca Antonelli, Davide Ardizzone, Praful Ravi, Aditya Bagrodia, Michal Mego, Siamak Daneshmand, Nicola Nicolai, Sebastiano Nazzani, Patrizia Giannatempo, Andrea Franza, Axel Heidenreich, Pia Paffenholz, Ragheed Saoud, Scott Eggener, Matthew Ho, Nathaniel Oswald, Kathleen Olson, Alexey Tryakin, Mikhail Fedyanin, Natacha Naoun, Christophe Javaud, Karim Fizazi, Jennifer M. King, Nabil Adra, Antoin Douglawi, Clint Cary, Christopher Sweeney, Christian D. Fankhauser
Publikováno v:
European Journal of Cancer. 182:144-154
Autor:
Achille Bottiglieri, Pierangela Sepe, Marco Stellato, Chiara Pircher, Giuseppe Fotia, Alberto Giovanni Leone, Valentina Guadalupi, Melanie Claps, Patrizia Giannatempo, Elena Verzoni, Giuseppe Procopio
Publikováno v:
Cancer Management and Research. 14:3071-3081
Renal cell carcinoma (RCC) is the fourteenth most common cancer worldwide. In about 55% of cases, it is diagnosed at a localised and/or locally advanced stage and therefore amenable to a curative approach. Although nephrectomy still represents the co